XPO1 inhibitors in the treatment of hematologic malignancies: From preclinical findings to clinical studies (notice n° 174686)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01670cam a2200289 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250112035953.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Rahmé, Ramy |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | XPO1 inhibitors in the treatment of hematologic malignancies: From preclinical findings to clinical studies |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2023.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 15 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Exportin 1 (XPO1) is a nuclear receptor that is involved in the phenomenon of nuclear export. A high expression of XPO1 is associated with reduced survival in hematologic malignancies. The inhibition of XPO1 was shown to be effective in multiple preclinical models. Selinexor was the main inhibitor tested in clinical trials, both in lymphoid and myeloid hemopathies. Its efficacy is generally moderate with an average pathology-dependent tolerability profile. Selinexor currently has temporary authorization for use in France in the treatment of multiple myeloma after failure of four lines of treatment and in non-Hodgkin lymphomas after failure of two lines. A better selection of patients with higher susceptibility to XPO1 inhibition and the development of second-generation inhibitors with lower digestive toxicity may revive the clinical development of XPO1 inhibitors. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | myeloma |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | leukemia |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | XPO1 |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | selinexor |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | lymphoma |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | myeloma |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | leukemia |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | XPO1 |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | selinexor |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | lymphoma |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Braun, Thorsten |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Hématologie | 29 | 3 | 2023-05-02 | p. 157-170 | 1264-7527 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/journal-hematologie-2023-3-page-157?lang=en">https://shs.cairn.info/journal-hematologie-2023-3-page-157?lang=en</a> |
Pas d'exemplaire disponible.
Réseaux sociaux